Form 8-K - Current report:
SEC Accession No. 0000950170-22-005695
Filing Date
2022-04-14
Accepted
2022-04-14 16:02:40
Documents
14
Period of Report
2022-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K clnn-20220414.htm   iXBRL 8-K 69282
2 EX-10.1 clnn-ex10_1.htm EX-10.1 427807
  Complete submission text file 0000950170-22-005695.txt   785405

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT clnn-20220414.xsd EX-101.SCH 3354
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT clnn-20220414_def.xml EX-101.DEF 28536
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT clnn-20220414_pre.xml EX-101.PRE 29690
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT clnn-20220414_lab.xml EX-101.LAB 36339
8 EXTRACTED XBRL INSTANCE DOCUMENT clnn-20220414_htm.xml XML 6635
Mailing Address 6550 SOUTH MILLROCK DRIVE, SUITE G50 SALT LAKE CITY UT 84121
Business Address 6550 SOUTH MILLROCK DRIVE, SUITE G50 SALT LAKE CITY UT 84121 801-676-9695
Clene Inc. (Filer) CIK: 0001822791 (see all company filings)

EIN.: 852828339 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39834 | Film No.: 22827216
SIC: 2834 Pharmaceutical Preparations